Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
Rajni Sethi, Nicholas SanfilippoDepartment of Radiation Oncology, New York University Langone Medical Center, New York, NY, USAAbstract: Hormonal deprivation therapy is well established for the treatment of locally advanced and metastatic prostate cancer, as well as the adjuvant treatment of some pa...
Saved in:
Main Authors: | Rajni Sethi, Nicholas Sanfilippo |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2009
|
Subjects: | |
Online Access: | https://doaj.org/article/72f39d373bb845b7bb19979e8e7aae54 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
by: Tunn UW, et al.
Published: (2013) -
Comparison between selected hormone and protein levels in serum and prostate tissue homogenates in men with benign prostatic hyperplasia and metabolic disorders
by: Grzesiak K, et al.
Published: (2018) -
Degarelix and its therapeutic potential in the treatment of prostate cancer
by: Christian Doehn, et al.
Published: (2009) -
Is there an optimal management for localized prostate cancer?
by: Jaspreet Singh, et al.
Published: (2010) -
Serum total prostate-specific antigen values in men with symptomatic prostate enlargement in Nigeria: role in clinical decision-making
by: Nnabugwu II, et al.
Published: (2014)